Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus VANOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus VANOBID.
FULVICIN-U/F vs VANOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism.
Category C
Category C
Antifungal
Antifungal and Corticosteroid Combination